Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: VSC011
MIFTS: 60

Vasculitis

Categories: Blood diseases, Bone diseases, Cardiovascular diseases, Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Vasculitis

About this section

MalaCards integrated aliases for Vasculitis:

Name: Vasculitis 11 19 58 75 28 53 5 41 43 14 63 16 71 33
Autoimmune Vasculitis 19 71
Angiitis 11 19
Vasculitis, Autoimmune 19
Systemic Vasculitis 58

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Immune diseases Cardiovascular diseases Bone diseases Blood diseases
See all MalaCards categories (disease lists)
ICD11: 33
Orphanet: 58  
Rare circulatory system diseases
Rare systemic and rhumatological diseases


External Ids:

Disease Ontology 11 DOID:865
MeSH 43 D014657
NCIt 49 C26912
SNOMED-CT 68 195375002
MESH via Orphanet 44 D014657 D056647
UMLS via Orphanet 72 C0042384 C0264939
Orphanet 58 ORPHA52759
UMLS 71 C0042384 C1328843
Sources

Summaries for Vasculitis

About this section

MedlinePlus: 41 Vasculitis is an inflammation of the blood vessels. It happens when the body's immune system attacks the blood vessel by mistake. It can happen because of an infection, a medicine, or another disease. The cause is often unknown. Vasculitis can affect arteries, veins and capillaries. Arteries are vessels that carry blood from the heart to the body's organs. Veins are the vessels that carry blood back to the heart. Capillaries are tiny blood vessels that connect the small arteries and veins. When a blood vessel becomes inflamed, it can: Narrow, making it more difficult for blood to get through. Close off completely so that blood can't get through. Stretch and weaken so much that it bulges. The bulge is called an aneurysm. If it bursts, it can cause dangerous bleeding inside the body. Symptoms of vasculitis can vary, but usually include fever, swelling and a general sense of feeling ill. The main goal of treatment is to stop the inflammation. Steroids and other medicines to stop inflammation are often helpful. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary: Vasculitis, also known as autoimmune vasculitis, is related to hypersensitivity vasculitis and churg-strauss syndrome, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Vasculitis is PRTN3 (Proteinase 3), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Innate Immune System. The drugs Alemtuzumab and Dapsone have been mentioned in the context of this disorder. Affiliated tissues include neutrophil, lung and heart, and related phenotypes are immune system and hematopoietic system

Orphanet: 58 Vasculitis represents a clinically heterogenous group of diseases of multifactorial etiology characterized by inflammation of either large-sized vessels (large-vessel vasculitis, e.g. Giant-cell arteritis and Takayasu arteritis; see these terms), medium-sized vessels (medium-vessel vasculitis e.g. polyarteritis nodosa and Kawasaki disease; see these terms), or small-sized vessels (small-vessel vasculitis, e.g. granulomatosis with polyangiitis, microscopic polyangiitis, immunoglobulin A vasculitis, and cutaneous leukocytoclastic angiitis; see these terms). Vasculitis occurs at any age, may be acute or chronic, and manifests with general symptoms such as fever, weight loss and fatigue, as well as more specific clinical signs depending on the type of vessels and organs affected. The degree of severity is variable, ranging from life or sight threatening disease (e.g. Behçet disease, see this term) to relatively minor skin disease.

PubMed Health : 63 Vasculitis: Vasculitis (vas-kyu-LI-tis) is a condition that involves inflammation in the blood vessels. The condition occurs if your immune system attacks your blood vessels by mistake. This may happen as the result of an infection, a medicine, or another disease or condition. “Inflammation” refers to the body’s response to injury, including injury to the blood vessels. Inflammation may involve pain, redness, warmth, swelling, and loss of function in the affected tissues. In vasculitis, inflammation can lead to serious problems. Complications depend on which blood vessels, organs, or other body systems are affected.

GARD: 19 An inflammatory process involving the wall of the vessels (large, medium, or small-sized vessels). The inflammatory process may cause necrosis or formation of granulomas in the vascular wall. It may be the result of an autoimmune disorder, infection, or malignancy. Representative examples include polyarteritis nodosa, temporal arteritis, Wegener granulomatosis, Kawasaki disease, Takayasu arteritis, and Henoch-Schonlein purpura.

Disease Ontology: 11 A vascular disease that is characterized by inflammation of the blood vessels.

Wikipedia: 75 Vasculitis is a group of disorders that destroy blood vessels by inflammation. Both arteries and veins... more...
Sources

Related Diseases for Vasculitis

About this section

Diseases in the Vasculitis family:

Autoimmune Vasculitis Secondary Vasculitis

Diseases related to Vasculitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2048)
# Related Disease Score Top Affiliating Genes
1 hypersensitivity vasculitis 33.4 TNF PRTN3 MPO MEFV CRP
2 churg-strauss syndrome 33.0 TNF THBD PRTN3 MPO
3 henoch-schoenlein purpura 33.0 VCAM1 TNF PRTN3 MPO MEFV ICAM1
4 livedoid vasculitis 32.9 PRTN3 APOH ADA2
5 rheumatoid vasculitis 32.9 VCAM1 TNF SELE ICAM1
6 allergic cutaneous vasculitis 32.8 PRTN3 MPO
7 microscopic polyangiitis 32.7 PRTN3 MPO ADA2
8 central nervous system vasculitis 32.7 TNFSF13B TNF PRTN3 MPO CRP
9 erythema elevatum diutinum 32.5 PRTN3 MPO CRP ADA2
10 kawasaki disease 32.5 VCAM1 TNF SELE ELANE CRP CD40LG
11 temporal arteritis 32.5 VWF TNFSF13B TNF PRTN3 MPO ICAM1
12 takayasu arteritis 32.4 VCAM1 TNF THBD SELE ICAM1 CRP
13 polyarteritis nodosa 32.4 VCAM1 TNF SELE PRTN3 MPO MEFV
14 granulomatosis with polyangiitis 32.4 TNFSF13B TNF SERPINA1 SELE PRTN3 MPO
15 autoimmune vasculitis 32.3 TNF PRTN3 MPO ELANE CRP
16 goodpasture syndrome 32.2 VCAM1 PRTN3 MPO CRP
17 granulomatous angiitis 32.1 PRTN3 CRP
18 arthus reaction 32.1 TNF ICAM1 ELANE
19 alpha-1-antitrypsin deficiency 32.0 TNF SERPINA1 PRTN3 MPO ELANE BPI
20 pyoderma gangrenosum 32.0 TNF MEFV APOH
21 buerger disease 32.0 VCAM1 ICAM1 CRP APOH
22 mononeuritis multiplex 32.0 TNF PRTN3 MPO CRP APOH ADA2
23 neutrophilic dermatosis, acute febrile 31.9 UBA1 TNF MPO MEFV CRP
24 exanthem 31.9 TNF PRTN3 MPO CRP
25 purpura 31.9 VWF TNFSF13B TNF THBD CRP APOH
26 glomerulonephritis 31.8 VCAM1 TNF PRTN3 MPO ICAM1 ELANE
27 crescentic glomerulonephritis 31.8 TNF PRTN3 MPO CRP
28 cryoglobulinemia 31.7 TNFSF13B TNF CD40LG
29 behcet syndrome 31.7 VWF VCAM1 TNFSF13B TNF THBD SELE
30 allergic disease 31.6 VCAM1 TNF SELE ICAM1
31 vascular disease 31.5 VWF VCAM1 TNF THBD SELE MPO
32 rapidly progressive glomerulonephritis 31.5 PRTN3 MPO ICAM1 ELANE CRP
33 sarcoidosis 1 31.5 TNF PRTN3 ICAM1 CRP
34 systemic scleroderma 31.4 TNFSF13B TNF PRTN3 CRP
35 systemic lupus erythematosus 31.4 VWF VCAM1 TNFSF13B TNF THBD SELE
36 peripheral nervous system disease 31.4 TNF PRTN3 MPO ICAM1 CRP
37 autoimmune disease 31.4 VCAM1 TNFSF13B TNF PRTN3 ICAM1 CRP
38 aortitis 31.4 TNF PRTN3 MPO CRP
39 sjogren syndrome 31.4 TNFSF13B PRTN3 ICAM1 CD40LG APOH
40 neuroretinitis 31.3 PRTN3 CRP
41 endocarditis 31.3 VCAM1 TNF CRP APOH
42 infective endocarditis 31.3 VWF PRTN3 MPO CRP
43 graves' disease 31.3 VCAM1 SELE MPO ICAM1
44 ulcerative colitis 31.3 TNF PRTN3 MPO CRP
45 erythema nodosum 31.3 VCAM1 TNF SELE ICAM1 CRP
46 connective tissue disease 31.3 VCAM1 TNFSF13B TNF PRTN3 MPO ICAM1
47 brucellosis 31.2 TNF MPO MEFV CRP
48 iga glomerulonephritis 31.2 SERPINA1 SELE PRTN3 MEFV ICAM1 CD40LG
49 pyoderma 31.2 TNF MEFV CRP APOH
50 spondyloarthropathy 1 31.2 TNF PRTN3 CRP CD40LG

Graphical network of the top 20 diseases related to Vasculitis:



Diseases related to Vasculitis
Sources

Symptoms & Phenotypes for Vasculitis

About this section

UMLS symptoms related to Vasculitis:


angina pectoris; chest pain; edema

MGI Mouse Phenotypes related to Vasculitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.03 CD40LG CRP CTSG CX3CL1 ELANE ICAM1
2 hematopoietic system MP:0005397 9.8 CD40LG CTSG CX3CL1 ELANE ICAM1 MEFV
3 mortality/aging MP:0010768 9.47 APOH CD40LG CTSG ELANE ICAM1 MEFV
Sources

Drugs & Therapeutics for Vasculitis

About this section

PubMed Health treatment related to Vasculitis: 63

Treatment for vasculitis will depend on the type of vasculitis you have, which organs are affected, and the severity of the condition. People who have severe vasculitis are treated with prescription medicines. Rarely, surgery may be done. People who have mild vasculitis may find relief with over-the-counter pain medicines, such as acetaminophen , aspirin , ibuprofen , or naproxen . The main goal of treating vasculitis is to reduce inflammation in the affected blood vessels . This usually is done by reducing or stopping the immune response that caused the inflammation.

Drugs for Vasculitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 183)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alemtuzumab Approved, Investigational Phase 4 216503-57-0
2
Dapsone Approved, Investigational Phase 4 80-08-0 2955
3
Mycophenolic acid Approved, Investigational Phase 4 24280-93-1 446541
4
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
5
Povidone K30 Approved, Experimental, Withdrawn Phase 4 9003-39-8 6917 131751496
6
Hydroxychloroquine Approved Phase 4 118-42-3 3652
7
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 4112 126941
8
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
9
Tofacitinib Approved, Investigational Phase 4 477600-75-2 9926791
10
Rituximab Approved Phase 4 174722-31-7
11
Azathioprine Approved Phase 4 446-86-6 2265
12
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
13 Melanocyte-Stimulating Hormones Phase 4
14 Adrenocorticotropic Hormone Phase 4
15
beta-Endorphin Phase 4
16 Gastrointestinal Agents Phase 4
17 Neuroprotective Agents Phase 4
18 Antiemetics Phase 4
19 Protective Agents Phase 4
20 Antitubercular Agents Phase 4
21 Antibiotics, Antitubercular Phase 4
22 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
23 glucocorticoids Phase 4
24 Dermatologic Agents Phase 4
25 Folic Acid Antagonists Phase 4
26 Folate Phase 4
27 Vitamin B9 Phase 4
28 Vitamin B Complex Phase 4
29 Protein Kinase Inhibitors Phase 4
30 Tin Fluorides Phase 4
31 Immunoglobulins Phase 4
32 Antibodies Phase 4
33 Antirheumatic Agents Phase 4
34 Immunosuppressive Agents Phase 4
35 Immunologic Factors Phase 4
36 Antimetabolites Phase 4
37 Antineoplastic Agents, Immunological Phase 4
38
Infliximab Approved Phase 3 170277-31-3
39
Belimumab Approved Phase 3 356547-88-1
40
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
41
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
42
Ranibizumab Approved Phase 2, Phase 3 347396-82-1
43
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
44
Coenzyme M Approved, Investigational Phase 3 3375-50-6 598 23662354
45
Colchicine Approved Phase 3 64-86-8 2833 6167
46
Acetaminophen Approved Phase 3 103-90-2 1983
47
Granisetron Approved, Investigational Phase 3 109889-09-0 3510 5284566
48
Clemastine Approved, Investigational Phase 3 15686-51-8 26987
49
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
50
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1

Interventional clinical trials:

(show top 50) (show all 225)
# Name Status NCT ID Phase Drugs
1 A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
2 Open-label, Single-center, Prospective Study on the Efficacy and Safety of Repository Corticotropin Injection (H.P. ACTHAR GEL) in the Treatment of Adults With Non-infectious Retinal Vasculitis Unknown status NCT03066869 Phase 4 H.P. ACTHAR GEL
3 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
4 Alemtuzumab for ANCA Associated Refractory Vasculitis - a Study of Safety and Efficacy Unknown status NCT01405807 Phase 4 Alemtuzumab
5 CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors a Prospective Randomized Study in 125 Patients Unknown status NCT00400075 Phase 4 azathioprine;cyclophosphamide
6 Short-Course Glucocorticoids and Rituximab in ANCA-Associated Vasculitis Completed NCT02169219 Phase 4 Glucocorticoids;Rituximab
7 Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease. Impact of Antirheumatic Treatment on Antibody Response. Completed NCT03762824 Phase 4
8 Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Comparison of Two Strategies Combining Steroids With or Without Immunosuppressants Completed NCT00307671 Phase 4 prednisone, methylprednisolone,cyclophosphamides;Cyclophosphamide, Azathioprine,prednisone,methylprednisolone;Mycophenolate mofetil,methotrexate
9 Hydroxychloroquine in ANCA Vasculitis Evaluation - A Multicentre, Randomised, Double-blind, Placebo-controlled Trial Recruiting NCT04316494 Phase 4 Hydroxychloroquine;Placebo
10 Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing Based on B-cell Reconstitution vs a Serologic ANCA Flare Recruiting NCT02749292 Phase 4 Rituximab
11 MAINtenance of Remission With RITuximab Versus Azathioprine for Patients With Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. A Prospective, Randomized, Controlled, Double-blind Study: the MAINRITSEG Trial Recruiting NCT03164473 Phase 4 Rituximab;Azathioprine;Placebo-rituximab;Placebo-azathioprine
12 Randomized Trial of Tofacitinib Versus Methotrexate for Maintenance Therapy in Granulomatosis With Polyangiitis Recruiting NCT04944524 Phase 4 Tofacitinib;Methotrexate
13 Low-dose Glucocorticoids Plus Rituximab Versus High-dose Glucocorticoids Plus Rituximab for Remission Induction in ANCA-associated Vasculitis; a Multicentre, Open Label, Randomised Control Trial Active, not recruiting NCT02198248 Phase 4 Rituximab;Glucocorticoids
14 Prevention of Relapses in PR3-ANCA-associated Vasculitis, a Tailored Approach Terminated NCT00128895 Phase 4 azathioprine
15 Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis Terminated NCT02626845 Phase 4 Rituximab
16 Treatment of ANCA-Associated Vasculitides : Corticosteroids and Pulse Cyclophosphamide Followed by Maintenance Therapy With Methotrexate or Azathioprine: a Prospective Multicenter Randomized Trial Unknown status NCT00349674 Phase 3 Azathioprine: 2 mg/kg/day;methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week
17 Comparative Study of the Efficacy of Induction Therapy With Cyclophosphamide or Mycophenolate Mofetil for Non-Life-Threatening Relapses of PR3- or MPO-ANCA Associated Vasculitis Unknown status NCT00103792 Phase 3 mycophenolate mofetil;cyclophosphamide
18 Multicenter, Randomized, Prospective Trial Comparing the Efficacy and Safety of Infliximab to That of Cyclophosphamide in Severe Behçet's Disease. ITAC : Induction Therapy With Anti-TNFα vs Cyclophosphamide in Severe Behçet Disease Unknown status NCT03371095 Phase 3 Infliximab;Cyclophosphamide
19 Randomized Trial of Intravenous Pulse Versus Oral Continuous Cyclophosphamide for Induction of Remission in Systemic ANCA-Associated Vasculitides Completed NCT00430105 Phase 2, Phase 3 cyclophosphamide
20 An International, Open Label, Randomised Controlled Trial Comparing Rituximab With Azathioprine as Maintenance Therapy in Relapsing ANCA-associated Vasculitis Completed NCT01697267 Phase 3 Azathioprine
21 MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis II Completed NCT01731561 Phase 3 Rituximab (Arm B);Rituximab (Arm A)
22 MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis Completed NCT00748644 Phase 3 Rituximab;Azathioprine
23 A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine Completed NCT02994927 Phase 3 Avacopan;Prednisone;Cyclophosphamide;Azathioprine
24 Extended Follow Up of the Mainritsan 2 Study. Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab: a Placebo- Controlled Randomized Trial Completed NCT02433522 Phase 3 rituximab;Placebo
25 Plasma Exchange and Glucocorticoid Dosing in the Treatment of Anti-neutrophil Cytoplasm Antibody Associated Vasculitis: an International Randomized Controlled Trial Completed NCT00987389 Phase 3 Glucocorticoids [Standard Dose];Glucocorticoids [Reduced Dose]
26 Phase III Study of Recombinant Human Interferon-alpha2a Versus Cyclosporin A for the Treatment of Ocular Behcet's Disease - a National,Randomised, Single-masked Controlled Trial (INCYTOB) Completed NCT00167583 Phase 3 Cyclosporin A;Interferon-alpha2a
27 Rituximab Therapy for the Induction of Remission and Tolerance in ANCA-Associated Vasculitis (ITN021AI) Completed NCT00104299 Phase 2, Phase 3 Rituximab plus cyclophosphamide placebo (rituximab group);Cyclophosphamide plus rituximab placebo (control group);Azathioprine;Methylprednisolone (or other glucocorticoid);Prednisone
28 A Randomised Clinical Trial of Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in ANCA Associated Vasculitis. Completed NCT00414128 Phase 2, Phase 3 mycophenolate mofetil;cyclophosphamide
29 A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis Completed NCT01663623 Phase 3 Azathioprine
30 Evaluation of a New Treatment Strategy for Patients With Microscopic Polyangiitis, Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) Without Poor Prognosis Factors Completed NCT00647166 Phase 3 corticosteroid and azathioprine;corticosteroid and placebo
31 The Use of a VEGF Inhibitor (Lucentis) in Refractory Macular Edema Due to Eales' Disease Completed NCT00384449 Phase 2, Phase 3 Ranibizumab
32 Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides Completed NCT02117453 Phase 3 Rosuvastatin;Placebo
33 A Double-blind, Randomised, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis in Subjects Receiving Standard of Care Therapy Completed NCT02020889 Phase 3 Placebo
34 Evaluation of Rituximab-based Regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Newly-Diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. Prospective, Randomized, Controlled, Double-blind Study Completed NCT02807103 Phase 3 Rituximab;Placebo-rituximab;Cyclophosphamide;Placebo-cyclophosphamide
35 Abatacept (CTLA4-Ig) for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's) (ABROGATE) Recruiting NCT02108860 Phase 3 Abatacept;placebo
36 Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease: a Prospective, Multicenter, Randomized, Open-label, Clinical Trial Recruiting NCT03323476 Phase 3 Maintenance (or initiation) of immunosuppressive treatment: Imurel®, Mabthera®,Cellcept®, Cortancyl®
37 COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases Recruiting NCT05236491 Phase 2, Phase 3
38 Evaluating Clinical and Immunological Effects of Rituximab With Cyclophosphamide Compared to Rituximab Alone in AAV Patients Recruiting NCT03942887 Phase 3 Rituximab;endoxan;Methylprednisolone;Prednisolone
39 Evaluation of Efficacy of Colchicine to Prevent Skin Relapses in Adult's IgA Vasculitis Recruiting NCT04008316 Phase 3 Colchicine
40 Evaluation of Glucocorticoids Plus Rituximab Compared to Glucocorticoids Plus Placebo for the Treatment of Patients With Newly-Diagnosed or Relapsing IgA Vasculitis: A Prospective, Randomized, Controlled, Double-blind Study Recruiting NCT05329090 Phase 3 Rituximab Injection;placebo
41 The Assessment of Prednisone In Remission Trial (TAPIR) - Centers of Excellence Approach Recruiting NCT01940094 Phase 3 5 mg Prednisone;0 mg Prednisone
42 A 52-week, Randomized, Double-blind, Double-dummy, Parallel-group, Multi-centre, Non-inferiority Study to Investigate the Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Receiving Standard of Care (SoC) Therapy Recruiting NCT05263934 Phase 3 Placebo matching mepolizumab;Placebo matching depemokimab
43 Evaluation of MEpolizumab-based Regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Eosinophilic Granulomatosis With Polyangiitis. Prospective, Randomized, Controlled, Double-blind Study Recruiting NCT05030155 Phase 3 Mepolizumab;cyclophosphamide/azathioprine;Placebo
44 The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach Active, not recruiting NCT01933724 Phase 3 5 mg prednisone;0 mg prednisone
45 The Effect of Some Drugs Used in Treatment of Vasculitis on the Complement System in Children Attending Assiut University Hospital. Active, not recruiting NCT03692416 Phase 3 Ibuprofen;Prednisone;Methotrexate
46 A Randomized, Double-blind, Active-controlled 52-week Study With an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab Compared to Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) in Patients Receiving Standard of Care Therapy Active, not recruiting NCT04157348 Phase 3
47 Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis Active, not recruiting NCT03920722 Phase 3 Rituximab;placebo
48 Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis Terminated NCT00307645 Phase 3 Cyclophosphamide;Mycophenolate mofetil;Azathioprine;Prednisone (and methylprednisolone)
49 GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases Terminated NCT01257802 Phase 3 depot leuprolide acetate 3.75 mg;Placebo
50 Intravenous Immunoglobulin After Relapse in Vasculitis (Microscopic Polyangiitis, Wegener's Granulomatosis and SHURG-STRAUSS Syndrome) During and After Corticosteroids and Immunosuppressant Therapies a Multicenter Prospective Trial Terminated NCT00307658 Phase 3 Intravenous immunoglobulins (human immunoglobulins G)

Search NIH Clinical Center for Vasculitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Pentoxifylline

Cochrane evidence based reviews: vasculitis

Sources

Genetic Tests for Vasculitis

About this section

Genetic tests related to Vasculitis:

# Genetic test Affiliating Genes
1 Vasculitis 28
Sources

Anatomical Context for Vasculitis

About this section

Organs/tissues related to Vasculitis:

MalaCards : Neutrophil, Lung, Heart, Skin, Bone, Endothelial, T Cells
Sources

Publications for Vasculitis

About this section

Articles related to Vasculitis:

(show top 50) (show all 32284)
# Title Authors PMID Year
1
Immunoglobulin A Vasculitis Following COVID-19: A French Multicenter Case Series. 62 41
36243405 2022
2
Positive Association of Plasma Trimethylamine-N-Oxide and Atherosclerosis in Patient with Acute Coronary Syndrome. 62 41
36420057 2022
3
'Vasculitic lung lesions' - Don't forget the heart! 41
36435557 2022
4
Osteopontin in antineutrophil cytoplasmic autoantibody-associated vasculitis: relation to disease activity, organ manifestation and immunosuppressive therapy. 53 62
20424002 2010
5
Structures of human proteinase 3 and neutrophil elastase--so similar yet so different. 53 62
20423453 2010
6
New developments in lung endothelial heterogeneity: Von Willebrand factor, P-selectin, and the Weibel-Palade body. 53 62
20490980 2010
7
Late onset of pANCA renal and pulmonary vasculitis in a girl affected by undifferentiated connective tissue disease. 53 62
20133348 2010
8
Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement--a prospective, open-label pilot trial. 53 62
20093349 2010
9
Genetics of vasculitis. 53 62
20051862 2010
10
Cutaneous vasculitis induced by TNF inhibitors: a report of three cases. 53 62
19812889 2010
11
Analysis of T-cell receptor usage in myeloperoxidase--antineutrophil cytoplasmic antibody-associated renal vasculitis. 53 62
19809783 2010
12
Pathogenesis of small vessel vasculitis associated with autoantibodies to neutrophil cytoplasmic antigens: new insights from animal models. 53 62
19823088 2010
13
Clinical and immunological features of drug-induced and infection-induced proteinase 3-antineutrophil cytoplasmic antibodies and myeloperoxidase-antineutrophil cytoplasmic antibodies and vasculitis. 53 62
19770659 2010
14
Clinical outcome and prognosis of anti-neutrophil cytoplasmic antibody-associated vasculitis in Japan. 53 62
20173346 2010
15
Henoch-schonlein purpura-a case report and review of the literature. 53 62
20508739 2010
16
Refractory antineutrophil cytoplasmic antibody-associated vasculitis successfully treated with rituximab: a case report. 53 62
20453447 2010
17
Copy number variation of FCGR3A rather than FCGR3B and FCGR2B is associated with susceptibility to anti-GBM disease. 53 62
19946017 2010
18
Confirmation of the genetic association of CTLA4 and PTPN22 with ANCA-associated vasculitis. 53 62
19951419 2009
19
Immunomodulator agent-related lymphoproliferative disorders. 53 62
19767727 2009
20
Hypergammaglobulinaemic purpura associated with alcoholic liver cirrhosis. 53 62
20055836 2009
21
[Henoch-Shönlein purpura]. 53 62
19345173 2009
22
[Retinal vein occlusion followed by ischemic optic neuropathy with anticardiolipin IgG antibody: a case report]. 53 62
19882933 2009
23
Antineutrophil cytoplasmic antibody-associated vasculitides and respiratory disease. 53 62
19809051 2009
24
Autoantibody screen in inflammatory myopathies high prevalence of antibodies to gliadin. 53 62
19758147 2009
25
Urinary CD4+ effector memory T cells reflect renal disease activity in antineutrophil cytoplasmic antibody-associated vasculitis. 53 62
19714581 2009
26
High-sensitivity detection of autoantibodies against proteinase-3 by a novel third-generation enzyme-linked immunosorbent assay. 53 62
19758130 2009
27
Clinical characteristics of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis caused by antithyroid drugs. 53 62
19491223 2009
28
EUROPLUS ANCA BIOCHIP mosaic: PR3 and MPO antigen microdots improve the laboratory diagnostics of ANCA-associated vasculitis. 53 62
19615371 2009
29
Retinoid X receptor beta polymorphisms do not explain functional differences in vitamins D and A response in Antineutrophil cytoplasmic antibody associated vasculitis patients. 53 62
19811264 2009
30
[Antineutrophil cytoplasmic antibodies and associated diseases]. 53 62
18834675 2009
31
Correlations between plasma levels of a fibronectin isoform subpopulation and C-reactive protein in patients with systemic inflammatory disease. 53 62
19489687 2009
32
Neutrophil-derived proteinase 3 induces kallikrein-independent release of a novel vasoactive kinin. 53 62
19494315 2009
33
Lack of association between E148Q MEFV variant and Kawasaki disease. 53 62
19026701 2009
34
[Anti-TNFalpha therapy in systemic autoimmune and/or inflammatory diseases]. 53 62
19349142 2009
35
Thiopurinemethyltransferase (TPMT) genotype and TPMT activity in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: relation to azathioprine maintenance treatment and adverse effects. 53 62
19366895 2009
36
Myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis with diffuse tubulointerstitial nephritis. 53 62
19557721 2009
37
Circulating neutrophil gelatinase-associated lipocalin: a useful biomarker for assessing disease activity of ANCA-associated vasculitis. 53 62
19181656 2009
38
Blockade of ICAM-1: a novel way of vasculitis treatment. 53 62
19249285 2009
39
Refractory central nervous system vasculitis and gastrocnemius myalgia syndrome in Crohn's disease successfully treated with anti-tumor necrosis factor-alpha antibody. 53 62
18304612 2009
40
The association of CTLA-4 and CD28 gene polymorphisms with idiopathic ischemic stroke in the paediatric population. 53 62
19284445 2009
41
Experimental autoimmune vasculitis: an animal model of anti-neutrophil cytoplasmic autoantibody-associated systemic vasculitis. 53 62
19264905 2009
42
Follow-up of avidity and titer of anti-myeloperoxidase antibodies in sera from patients with primary ANCA-associated vasculitis. 53 62
19301200 2009
43
Review article: The role of CD4(+) T cells in ANCA-associated systemic vasculitis. 53 62
19143940 2009
44
Acute Chlamydia pneumoniae infection in the pathogenesis of autoimmune diseases. 53 62
19151119 2009
45
Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis. 53 62
19284577 2009
46
Giant cell arteritis: A rare cause of posterior vasculitis. 53 62
19668553 2009
47
Advances in the use of biologic agents for the treatment of systemic vasculitis. 53 62
19077713 2009
48
Monocyte chemoattractant protein 1 is a prognostic marker in ANCA-associated small vessel vasculitis. 53 62
19587833 2009
49
Classification of clinical subtypes, patient survival, kidney prognosis, and relapse in patients with MPO-ANCA-associated vasculitis: a single-center experience. 53 62
19521745 2009
50
Two types of myeloperoxidase-antineutrophil cytoplasmic autoantibodies with a high affinity and a low affinity in small vessel vasculitis. 53 62
19646343 2009
Sources

Variations for Vasculitis

About this section

ClinVar genetic disease variations for Vasculitis:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 CCM2 NM_031443.4(CCM2):c.1234C>T (p.Arg412Trp) SNV Uncertain Significance
 523540 rs544276945 GRCh37: 7:45115555-45115555
GRCh38: 7:45075956-45075956
2 COL4A2-AS2, COL4A2 NM_001846.4(COL4A2):c.1776+13A>G SNV Uncertain Significance
 523445 rs1555330577 GRCh37: 13:111114744-111114744
GRCh38: 13:110462397-110462397
Sources

Expression for Vasculitis

About this section
Search GEO for disease gene expression data for Vasculitis.
Sources

Pathways for Vasculitis

About this section

Pathways related to Vasculitis according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Cytokine Signaling in Immune system 66
Show member pathways
 13.1 VCAM1 TNFSF13B TNF PRTN3 ICAM1 CTSG
2
Innate Immune System 66
Show member pathways
 13.05 VCAM1 UBA1 TNFSF13B TNF SERPINA1 PRTN3
3
Extracellular matrix organization 66
Show member pathways
 12.54 VWF VCAM1 ICAM1 ELANE CTSG
4
Complement cascade 66
Show member pathways
 12.41 SELE ICAM1 ELANE CX3CL1 CRP
5
NF-kappaB Signaling 3
12.35 CD40LG MPO TNF TNFSF13B VCAM1
6
Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) 66
Show member pathways
 12.34 VWF THBD SERPINA1 PRTN3
7
Defensins 66
Show member pathways
 12.14 BPI CTSG ELANE PRTN3
8
Matrix metalloproteinases 74
Show member pathways
 11.76 TNF ELANE CTSG
9
p53 transcriptional gene network 74
11.72 TNF ICAM1 CX3CL1
10
C-MYB transcription factor network 61
11.64 PRTN3 MPO ELANE
11
Apoptosis and survival Anti-apoptotic TNFs/NF-kB/Bcl-2 pathway 22
Show member pathways
 11.59 TNFSF13B TNF CD40LG
12
Extrafollicular B cell activation by SARS-CoV-2 74
11.56 TNF CRP CD40LG
13
IL 10 signaling pathway 67
11.48 TNFSF13B TNF CD40LG
14
miRNAs involvement in the immune response in sepsis 74
11.42 VCAM1 TNF ICAM1 ELANE
15
Photodynamic therapy-induced NF-kB survival signaling 74
Show member pathways
 11.35 CD40LG ICAM1 SELE TNF VCAM1
16
Netrin-UNC5B signaling pathway 74
11.27 VCAM1 TNF SELE ICAM1
17
Thromboxane A2 receptor signaling 61
11.11 VCAM1 SELE ICAM1
18
Beta2 integrin cell surface interactions 61
11.01 VCAM1 ICAM1 CD40LG
19
LDL Oxidation in Atherogenesis 64
10.46 VCAM1 TNF MPO ICAM1
Sources

GO Terms for Vasculitis

About this section

Cellular components related to Vasculitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 10.45 APOH BPI CTSG ELANE ICAM1 MPO
2 extracellular region GO:0005576 10.29 ADA2 APOH BPI CD40LG CRP CTSG
3 cell surface GO:0009986 10.22 APOH CD40LG CX3CL1 ELANE ICAM1 THBD
4 external side of plasma membrane GO:0009897 10.15 VCAM1 TNF THBD SELE ICAM1 CD40LG
5 collagen-containing extracellular matrix GO:0062023 10.1 VWF SERPINA1 PRTN3 ICAM1 ELANE CTSG
6 extracellular space GO:0005615 9.88 ADA2 APOH BPI CD40LG CRP CTSG
7 azurophil granule lumen GO:0035578 9.73 ADA2 BPI CTSG ELANE MPO PRTN3

Biological processes related to Vasculitis according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 10.26 TNF SELE MEFV CX3CL1 CRP CD40LG
2 immune response GO:0006955 10.13 BPI CD40LG CTSG CX3CL1 TNF TNFSF13B
3 cellular response to amyloid-beta GO:1904646 10.01 VCAM1 TNF ICAM1
4 defense response to bacterium GO:0042742 10 BPI CTSG ELANE MPO TNF
5 defense response to fungus GO:0050832 9.89 MPO ELANE CTSG
6 positive regulation of I-kappaB phosphorylation GO:1903721 9.87 TNF CX3CL1
7 response to yeast GO:0001878 9.86 MPO ELANE
8 leukocyte cell-cell adhesion GO:0007159 9.86 CD40LG ICAM1 SELE VCAM1
9 membrane to membrane docking GO:0022614 9.81 VCAM1 ICAM1
10 leukocyte tethering or rolling GO:0050901 9.8 VCAM1 TNF SELE
11 hemostasis GO:0007599 9.73 VWF THBD SERPINA1
12 cell communication GO:0007154 9.72 TNFSF13B TNF CD40LG
13 response to gold nanoparticle GO:1990268 9.67 TNF MPO
14 signaling GO:0023052 9.58 TNFSF13B TNF CD40LG
15 leukocyte migration involved in inflammatory response GO:0002523 9.56 TNF SELE ELANE CX3CL1
16 leukocyte migration GO:0050900 9.55 TNF SELE ICAM1 ELANE
17 response to lipopolysaccharide GO:0032496 9.4 VCAM1 TNF THBD SELE MPO ELANE

Molecular functions related to Vasculitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.86 VWF TNF SERPINA1 ELANE
2 heparin binding GO:0008201 9.65 MPO ELANE CTSG APOH ADA2
3 tumor necrosis factor receptor binding GO:0005164 9.63 TNFSF13B TNF CD40LG
4 integrin binding GO:0005178 9.32 VWF VCAM1 ICAM1 CX3CL1 CD40LG
Sources

Sources for Vasculitis

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....